Latest On Vascular Biogenics Ltd (VBLT):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-16 05:44 EST | News | VBL Therapeutics GAAP EPS of -$0.03 | N/A |  |
| 2023-03-14 11:26 EST | News | VBL Therapeutics GAAP EPS of -$0.42, revenue of $0.7M | N/A | |
| 2023-03-01 17:52 EST | News | Vascular Biogenics stock dips amid sale of manufacturing facility to Aleph Farms | N/A | |
| 2023-02-23 20:53 EST | News | Vascular Biogenics rises 85% on all-stock merger deal with Notable Labs | N/A | |
| 2022-11-15 09:31 EST | News | VBL Therapeutics GAAP EPS of -$0.12 in-line, revenue of $0.5M beats by $0.3M | N/A | |
| 2022-09-02 06:50 EST | News | VBL Therapeutics receives non-compliance letter from Nasdaq | N/A | |
| 2022-08-15 23:12 EST | News | VBL Therapeutics GAAP EPS of -$0.12 | N/A | |
| 2022-08-02 22:22 EST | News | Vascular Biogenics cuts 35% of workforce to save costs | N/A | |
| 2022-07-20 13:33 EST | News | Vascular Biogenics cut to Neutral at HC Wainwright after trial failure sinks stock 79% | N/A | |
| 2022-07-19 23:40 EST | News | VBL Therapeutics sinks ~76% after late-stage trial for ovarian cancer treatment fails | N/A | |
| 2022-05-17 19:04 EST | News | VBL Therapeutics GAAP EPS of -$0.13 misses by $0.01, revenue of $0.11M misses by $0.09M | N/A | |
| 2022-05-17 19:04 EST | News | Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-16 21:55 EST | News | VBL Therapeutics Q1 2022 Earnings Preview | N/A | |
| 2022-04-26 22:06 EST | News | VBL Therapeutics stock rises 10% on FDA fast track status for VB-111 to treat ovarian cancer | N/A | |
| 2022-04-14 14:08 EST | News | Vascular Biogenics (VBLT) Presents at the KOL Event on Ovarian Cancer - Slideshow | N/A | |
| 2022-03-23 16:43 EST | News | VBL Therapeutics FY 2021 Earnings Preview | N/A | |
| 2022-03-23 16:42 EST | News | VBL Therapeutics GAAP EPS of -$0.45 misses by $0.03, revenue of $0.77M beats by $0.02M | N/A | |
| 2022-03-23 16:42 EST | News | Vascular Biogenics Ltd. 2021 Q4 - Results - Earnings Call Presentation | N/A | |
| 2022-03-23 16:42 EST | News | Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-08 21:25 EST | News | VBL Therapeutics gets safety committee nod to proceed with phase 3 ovarian cancer trial | N/A | |
| 2021-11-15 14:40 EST | News | VBL Therapeutics EPS beats by $0.01, beats on revenue | N/A | |
| 2021-11-15 14:39 EST | News | Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-13 05:57 EST | News | VBL Therapeutics Q3 2021 Earnings Preview | N/A | |
| 2021-10-05 18:02 EST | News | VBL Therapeutics appoints CFO; sets up operations in U.S. | N/A | |
| 2021-09-22 09:35 EST | News | VBL Therapeutics on go with Phase 3 VB-111 study in ovarian cancer after DSMC recommendation | N/A | |
| 2021-09-04 00:36 EST | News | Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump | N/A | |
| 2021-08-30 21:08 EST | News | VBL Therapeutics jumps 12% after resuming U.S. enrollment in late-stage OVAL trial | N/A | |
| 2021-08-17 02:50 EST | News | Vascular Biogenics Ltd (VBLT) CEO Dror Harats on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-15 12:22 EST | News | VBL Therapeutics Q2 2021 Earnings Preview | N/A | |
| 2021-07-22 07:09 EST | News | VBL Therapeutics climbs on amendment to cancer study | N/A | |
| 2021-07-22 06:59 EST | News | VBL Therapeutics: Feeling Bullish After VB-111 Clinical Trial Amendment | N/A | |
| 2021-07-22 06:56 EST | News | Vascular Biogenics trades lower after an update on ovarian cancer study | N/A | |
| 2021-04-09 12:14 EST | News | Vascular Biogenics prices $25M stock offering | N/A | |
| 2021-04-08 17:49 EST | News | Vascular Biogenics proposes capital raise | N/A | |
| 2021-03-29 19:42 EST | News | Vascular Biogenics Ltd.'s (VBLT) CEO Dror Harats on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-03-25 22:50 EST | News | VBL Therapeutics EPS misses by $0.02, misses on revenue | N/A | |
| 2021-03-25 22:49 EST | News | Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-03-17 11:01 EST | News | Vascular Biogenics (VBLT) Investor Presentation - Slideshow | N/A | |
| 2021-03-04 10:57 EST | News | VBL Therapeutics' stock up on late-stage VB-111 ovarian cancer study results | N/A | |
| 2021-03-02 21:10 EST | News | VBL Therapeutics: A Speculative Play With An Enticing Risk-Reward Profile | N/A | |
| 2021-02-24 12:37 EST | Analyst Rating | The Analyst Target Price has increased from $4.55 to $5. | Buy | |
| 2021-02-22 10:59 EST | News | VBL Therapeutics gets green light for VB-111 study in ovarian cancer, shares up 16% | N/A | |
| 2021-01-29 08:46 EST | Analyst Rating | The Analyst Target Price has increased from $4.35 to $4.55. | Buy | |
| 2021-01-27 22:44 EST | News | Dosing underway in VBL Therapeutics' VB-201 mid-stage study in COVID-19 | N/A | |
| 2021-01-15 17:06 EST | News | Aspire capital fund to purchase up to $20M of ordinary shares of VBL therapeutics | N/A | |
| 2021-01-15 17:06 EST | News | VBL Therapeutics inks $20M stock purchase agreement with Aspire Capital; shares ahead 10% premarket | N/A | |
| 2021-01-14 10:02 EST | Analyst Rating | The Analyst Target Price has increased from $3.85 to $4.35. | Buy | |
| 2020-12-29 23:41 EST | News | VBL Therapeutics expands the ovarian cancer trial in Europe | N/A | |
| 2020-11-26 21:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-17 22:36 EST | News | VBL Therapeutics EPS beats by $0.01, misses on revenue | N/A | |
About Vascular Biogenics Ltd (VBLT):
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase 3 clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and in Phase 1/2 clinical trials for recurrent platinum-resistant ovarian cancer, as well as in Phase 2 clinical trials to treat GI tumors and has completed phase 2 clinical trial for the treatment of thyroid cancer. In addition, it is developing VB-511, an anti-angiogenic candidate for oncology; and VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases. Further, the company is developing VB-201, a Lecinoxoid-based compound used to treat atherosclerosis that has completed phase II clinical, as well as in pre-clinical stage for the treatment of NASH and renal fibrosis. It is also developing VB-601 and 611 for immuno-oncology and anti-inflammatory applications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Modi'in, Israel.
General
- Name Vascular Biogenics Ltd
- Symbol VBLT
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 38
- Fiscal Year EndDecember
- IPO Date2014-10-01
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.vblrx.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 100.27
- Price/Book (Most Recent Quarter) 2.7
- Enterprise Value Revenue 78.28
View More
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.14
- Operating Margin -2737%
- Return on Assets -29%
- Return on Equity -58%
- Revenue 843000
- Earnings Per Share -$0.50
- Revenue Per Share $0.02
- Gross Profit 399000
- Quarterly Earnings Growth 144.3%
View More
Highlights
- Market Capitalization 97.82 million
- EBITDA -19183000
- Analyst Target Price $5
- Book Value Per Share $0.78
View More
Share Statistics
- Shares Outstanding 48.19 million
- Shares Float 28.58 million
- % Held by Insiders 2299%
- % Held by Institutions 23.82%
- Shares Short 3.28 million
- Shares Short Prior Month 1.78 million
- Short Ratio 1.61
- Short % of Float 9%
- Short % of Shares Outstanding 7%
View More
Technicals
- Beta 0.88
- 52 Week High $3.17
- 52 Week Low $1.01
- 50 Day Moving Average 2.21
- 200 Day Moving Average 1.68
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Vascular Biogenics Ltd (VBLT) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Vascular Biogenics Ltd (VBLT) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-16 | $N/A | -$0.12 | -$0.13 | 7.69% |
| 2020-06-30 | 2020-08-13 | $366000 | -$0.14 | -$0.13 | -7.69% |
| 2020-03-31 | 2020-05-14 | $366000 | -$0.15 | -$0.17 | 10.45% |
| 2019-12-31 | 2020-03-19 | $126000 | -$0.16 | -$0.14 | -14.29% |
| 2019-09-30 | 2019-11-14 | $79000 | -$0.14 | -$0.14 | -2.41% |
| 2019-06-30 | 2019-08-13 | $138000 | -$0.13 | -$0.13 | 0% |
| 2019-03-31 | 2019-05-15 | $219000 | -$0.12 | -$0.06 | -100% |
| 2018-12-31 | 2019-03-28 | $141000 | -$0.10 | -$0.17 | 41.18% |
| 2018-09-30 | 2018-11-20 | $101000 | -$0.15 | -$0.12 | -25% |
| 2018-06-30 | 2018-08-16 | $180000 | -$0.13 | -$0.18 | 27.78% |
| 2018-03-31 | 2018-05-17 | $163000 | -$0.24 | -$0.21 | -14.29% |
| 2017-12-31 | 2018-03-15 | $13.86 million | $0.24 | -$0.06 | 500% |
| 2017-09-30 | 2017-11-14 | $N/A | -$0.24 | -$0.18 | -35.82% |
| 2017-06-30 | 2017-08-14 | $N/A | -$0.18 | -$0.18 | 0% |
| 2017-03-31 | 2017-05-15 | $N/A | -$0.19 | -$0.16 | -18.75% |
| 2016-12-31 | 2017-03-27 | $N/A | -$0.17 | -$0.14 | -24.36% |
| 2016-09-30 | 2016-11-10 | $N/A | -$0.12 | -$0.15 | 18.64% |
| 2016-06-30 | 2016-08-15 | $N/A | -$0.14 | -$0.20 | 30% |
| 2016-03-31 | 2016-05-13 | $N/A | -$0.21 | -$0.16 | -28.6% |
| 2015-12-31 | 2016-03-29 | $N/A | -$0.14 | -$0.28 | 50% |
| 2015-09-30 | 2015-11-12 | $N/A | -$0.29 | -$0.19 | -52.63% |
| 2015-06-30 | 2015-08-13 | $N/A | -$0.15 | -$0.17 | 11.76% |
| 2015-03-31 | 2015-05-12 | $N/A | -$0.15 | -$0.23 | 34.78% |
| 2014-12-31 | 2015-03-25 | $N/A | -$0.25 | -$0.24 | -4.17% |
| 2014-09-30 | 2014-11-05 | $N/A | -$2.45 | -$0.36 | -580.56% |
Vascular Biogenics Ltd (VBLT) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | 4.75 million | 4.75 million | 4.64 million | 3.8 million |
| Income Before Tax | N/A | -5.35 million | -5.35 million | -5.73 million | -4.86 million |
| Selling General Administrative | N/A | 1.17 million | 1.17 million | 1.27 million | 1.23 million |
| Gross Profit | N/A | 313000 | 313000 | 81000 | 49000 |
| Ebit | N/A | -4.91 million | -4.9 million | -5.83 million | -4.98 million |
| Operating Income | N/A | -5.61 million | -5.61 million | -5.83 million | -4.98 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | 366000 | 366000 | 126000 | 79000 |
| Cost of Revenue | N/A | 53000 | 53000 | 45000 | 30000 |
| Total Other Income Expense Net | N/A | N/A | N/A | 102000 | 122000 |
| Net Income From Continuing Operations | N/A | -5.35 million | -5.35 million | -5.73 million | -4.86 million |
| Net Income Applicable to Common Shares | -5.78 million | N/A | N/A | -5.73 million | -4.86 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | -5.99 million | 8.99 million | -9.53 million | 18.5 million |
| Change to Liabilities | 858000 | N/A | N/A | 1.94 million | -915000 |
| Total Cash Flow from Investing Activities | -1.11 million | N/A | N/A | -9.05 million | 18 million |
| Net Borrowings | -207000 | N/A | N/A | -203000 | -200000 |
| Total Cash Flow from Financial Activities | N/A | 16.45 million | 252000 | -201000 | -200000 |
| Change to Operating Activities | 507000 | N/A | N/A | -924000 | 859000 |
| Change in Cash | N/A | 3.74 million | 3.4 million | -12.88 million | 14.04 million |
| Total Cash from Operating Activities | -3.62 million | -6.73 million | -5.84 million | -3.65 million | -3.79 million |
| Depreciation | N/A | 409000 | 418000 | 433000 | 429000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | 500000 | -500000 |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | 112000 | -230000 | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 382000 | N/A | N/A | 630000 | 695000 |
| Capital Expenditures | N/A | 9000 | 11000 | 20000 | N/A |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | 10.14 million | 11.62 million | 12.78 million | 11.98 million |
| Total Stockholder Equity | N/A | 42.54 million | 31.44 million | 35.84 million | 41.16 million |
| Other Current Liabilities | 583000 | N/A | N/A | 386000 | 5.63 million |
| Total Assets | N/A | 52.67 million | 43.06 million | 48.62 million | 53.14 million |
| Common Stock | 108000 | N/A | N/A | 73000 | 73000 |
| Other Current Assets | 1.26 million | 1.7 million | 1.25 million | 1.24 million | 1.64 million |
| Retained Earnings | -225.07 million | -219.29 million | -213.46 million | -208.1 million | -202.37 million |
| Other Liabilities | 1.31 million | N/A | N/A | 1.89 million | 1.96 million |
| Other Assets | 615000 | N/A | N/A | 806000 | 503000 |
| Cash | N/A | 16.7 million | 12.94 million | 9.44 million | 22.32 million |
| Total Current Liabilities | 7.41 million | 6.66 million | 7.91 million | 8.73 million | 7.69 million |
| Other Stockholder Equity | 10.39 million | N/A | N/A | 7.9 million | 7.95 million |
| Property, Plant & Equipment | 9.07 million | N/A | N/A | 10.04 million | 10.45 million |
| Total Current Assets | 38.18 million | 42.72 million | 32.55 million | 37.78 million | 42.19 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 37.17 million | N/A | N/A | 35.84 million | 41.16 million |
| Short Term Investments | N/A | 24.05 million | 18.14 million | 27.1 million | 18.23 million |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 6.24 million | 2.24 million | 2.29 million | 3.33 million | 1.26 million |
Vascular Biogenics Ltd (VBLT) Chart:
Vascular Biogenics Ltd (VBLT) News:
Below you will find a list of latest news for Vascular Biogenics Ltd (VBLT) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Vascular Biogenics Ltd (VBLT) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest VBLT Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 6:10 PM EST | 900 | $1.34 |
| Jun 13, 2022 6:32 PM EST | 100 | $1.33 |
| Jun 13, 2022 2:03 PM EST | 500 | $1.37 |
Vascular Biogenics Ltd (VBLT) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-09 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1603207/999999999520001382/9999999995-20-001382-index.htm |
| 2017-09-28 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1603207/000000000017034586/0000000000-17-034586-index.htm |
| 2017-10-24 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1603207/000000000017037631/0000000000-17-037631-index.htm |
| 2017-12-28 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1603207/000000000017045248/0000000000-17-045248-index.htm |
| 2020-06-05 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1603207/000000000020005023/0000000000-20-005023-index.htm |
| 2018-06-28 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1603207/000090266418002681/0000902664-18-002681-index.htm |
| 2019-01-17 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1603207/000090266419000271/0000902664-19-000271-index.htm |
| 2020-05-18 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1603207/000091957420003749/0000919574-20-003749-index.htm |
| 2018-07-03 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1603207/000110465918043704/0001104659-18-043704-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1603207/000110465919008595/0001104659-19-008595-index.htm |
| 2019-08-01 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1603207/000114420419037103/0001144204-19-037103-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1603207/000117891320000443/0001178913-20-000443-index.htm |
| 2020-08-03 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1603207/000117891320002210/0001178913-20-002210-index.htm |
| 2016-06-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312516613247/0001193125-16-613247-index.htm |
| 2016-06-07 | 6-K/A | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312516614638/0001193125-16-614638-index.htm |
| 2016-06-07 | 6-K/A | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312516614640/0001193125-16-614640-index.htm |
| 2016-06-07 | 6-K/A | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312516614642/0001193125-16-614642-index.htm |
| 2016-06-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312516614720/0001193125-16-614720-index.htm |
| 2016-06-09 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1603207/000119312516617874/0001193125-16-617874-index.htm |
| 2016-06-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312516617939/0001193125-16-617939-index.htm |
| 2016-06-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312516627053/0001193125-16-627053-index.htm |
| 2016-08-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312516681287/0001193125-16-681287-index.htm |
| 2016-09-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312516715965/0001193125-16-715965-index.htm |
| 2016-10-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312516737701/0001193125-16-737701-index.htm |
| 2016-11-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312516761648/0001193125-16-761648-index.htm |
| 2016-11-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312516765126/0001193125-16-765126-index.htm |
| 2016-11-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312516778752/0001193125-16-778752-index.htm |
| 2016-12-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312516782469/0001193125-16-782469-index.htm |
| 2016-12-01 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1603207/000119312516782485/0001193125-16-782485-index.htm |
| 2017-01-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312517003688/0001193125-17-003688-index.htm |
| 2017-01-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312517005233/0001193125-17-005233-index.htm |
| 2017-02-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312517049359/0001193125-17-049359-index.htm |
| 2017-03-27 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1603207/000119312517096449/0001193125-17-096449-index.htm |
| 2017-06-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312517193722/0001193125-17-193722-index.htm |
| 2017-06-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312517207146/0001193125-17-207146-index.htm |
| 2017-06-22 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312517210499/0001193125-17-210499-index.htm |
| 2017-08-14 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1603207/000119312517257397/0001193125-17-257397-index.htm |
| 2017-09-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312517283839/0001193125-17-283839-index.htm |
| 2017-11-16 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses | https://www.sec.gov/Archives/edgar/data/1603207/000119312517345658/0001193125-17-345658-index.htm |
| 2017-11-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000119312517348222/0001193125-17-348222-index.htm |
| 2017-11-20 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1603207/000119312517348223/0001193125-17-348223-index.htm |
| 2020-05-26 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1603207/000121390020013429/0001213900-20-013429-index.htm |
| 2017-10-11 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1603207/000149315217011506/0001493152-17-011506-index.htm |
| 2017-10-11 | 20-F/A | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1603207/000149315217011507/0001493152-17-011507-index.htm |
| 2017-10-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315217011855/0001493152-17-011855-index.htm |
| 2017-10-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315217011893/0001493152-17-011893-index.htm |
| 2017-11-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315217012434/0001493152-17-012434-index.htm |
| 2017-11-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315217013015/0001493152-17-013015-index.htm |
| 2017-11-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315217013682/0001493152-17-013682-index.htm |
| 2017-12-18 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1603207/000149315217014727/0001493152-17-014727-index.htm |
| 2018-01-02 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1603207/000149315218000039/0001493152-18-000039-index.htm |
| 2018-01-02 | F-3/A | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1603207/000149315218000040/0001493152-18-000040-index.htm |
| 2018-01-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315218000061/0001493152-18-000061-index.htm |
| 2018-02-26 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1603207/000149315218002598/0001493152-18-002598-index.htm |
| 2018-03-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315218003043/0001493152-18-003043-index.htm |
| 2018-03-15 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1603207/000149315218003377/0001493152-18-003377-index.htm |
| 2018-03-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315218003378/0001493152-18-003378-index.htm |
| 2018-05-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315218007350/0001493152-18-007350-index.htm |
| 2018-06-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315218008457/0001493152-18-008457-index.htm |
| 2018-06-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315218009260/0001493152-18-009260-index.htm |
| 2018-06-27 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1603207/000149315218009261/0001493152-18-009261-index.htm |
| 2018-08-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315218012124/0001493152-18-012124-index.htm |
| 2018-10-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315218014463/0001493152-18-014463-index.htm |
| 2018-10-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315218014764/0001493152-18-014764-index.htm |
| 2018-11-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315218016323/0001493152-18-016323-index.htm |
| 2018-11-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315218016541/0001493152-18-016541-index.htm |
| 2018-12-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315218017660/0001493152-18-017660-index.htm |
| 2019-03-28 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1603207/000149315219004066/0001493152-19-004066-index.htm |
| 2019-05-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315219007190/0001493152-19-007190-index.htm |
| 2019-05-17 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1603207/000149315219007746/0001493152-19-007746-index.htm |
| 2019-05-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315219007748/0001493152-19-007748-index.htm |
| 2019-06-27 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1603207/000149315219009803/0001493152-19-009803-index.htm |
| 2019-08-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315219012116/0001493152-19-012116-index.htm |
| 2019-08-29 | 6-K/A | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315219013510/0001493152-19-013510-index.htm |
| 2019-11-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315219016326/0001493152-19-016326-index.htm |
| 2019-11-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315219017156/0001493152-19-017156-index.htm |
| 2019-12-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315219019621/0001493152-19-019621-index.htm |
| 2019-12-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315219019863/0001493152-19-019863-index.htm |
| 2020-03-19 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1603207/000149315220004312/0001493152-20-004312-index.htm |
| 2020-03-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315220004314/0001493152-20-004314-index.htm |
| 2020-03-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315220004766/0001493152-20-004766-index.htm |
| 2020-05-11 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1603207/000149315220008170/0001493152-20-008170-index.htm |
| 2020-05-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315220008172/0001493152-20-008172-index.htm |
| 2020-05-12 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1603207/000149315220008325/0001493152-20-008325-index.htm |
| 2020-05-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315220008326/0001493152-20-008326-index.htm |
| 2020-05-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315220008587/0001493152-20-008587-index.htm |
| 2020-05-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315220010001/0001493152-20-010001-index.htm |
| 2020-06-01 | F-1 | Registration statement for certain foreign private issuers | https://www.sec.gov/Archives/edgar/data/1603207/000149315220010237/0001493152-20-010237-index.htm |
| 2020-06-08 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1603207/000149315220010715/0001493152-20-010715-index.htm |
| 2020-07-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315220014250/0001493152-20-014250-index.htm |
| 2020-08-05 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1603207/000149315220014740/0001493152-20-014740-index.htm |
| 2020-08-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315220015301/0001493152-20-015301-index.htm |
| 2020-08-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315220015429/0001493152-20-015429-index.htm |
| 2020-08-26 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1603207/000149315220016776/0001493152-20-016776-index.htm |
| 2020-10-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315220019299/0001493152-20-019299-index.htm |
| 2020-10-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315220019613/0001493152-20-019613-index.htm |
| 2020-10-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000149315220020093/0001493152-20-020093-index.htm |
| 2018-06-26 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1603207/000153561018000093/0001535610-18-000093-index.htm |
| 2019-01-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1603207/000153561019000039/0001535610-19-000039-index.htm |
| 2020-01-21 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1603207/000153561020000051/0001535610-20-000051-index.htm |
| 2017-05-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000155837017004301/0001558370-17-004301-index.htm |
| 2017-08-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1603207/000155837017006602/0001558370-17-006602-index.htm |
| 2016-08-25 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1603207/000161577416006946/0001615774-16-006946-index.htm |
| 2016-08-25 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1603207/000161577416006948/0001615774-16-006948-index.htm |
| 2016-09-20 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1603207/000161577416007265/0001615774-16-007265-index.htm |
| 2017-09-18 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1603207/000161577417005152/0001615774-17-005152-index.htm |
| 2018-02-21 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1603207/000161577418001352/0001615774-18-001352-index.htm |
| 2018-01-04 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1603207/999999999518000044/9999999995-18-000044-index.htm |
| 2020-06-09 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1603207/999999999520001382/9999999995-20-001382-index.htm |
| 2018-04-27 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1603207/999999999718005323/9999999997-18-005323-index.htm |